Triglycerides Glucose IndexNCT07154186
Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
An observational study of Triglycerides Glucose Index and Angiographic Profiling, run by Sohag University at 1 site in Egypt.
Trial summary
This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Triglycerides Glucose Index, Angiographic Profiling, Non-Diabetic
- What is being tested?
- Coronary Angiographic Assessment
- How many people
- 180 participants
- Where
- 1 siteEgypt
- Study dates
- 4 Sep 2025to 1 Feb 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This cross-sectional study will be conducted at Sohag University Hospitals, following approval from the institutional ethics committee.
Who may be able to join
- Age ≥18 years old.
- Both sexes.
- Non-diabetic patients [no history of diabetes, hemoglobin A1C (HbA1C) < 6.5%, fasting glucose < 126 mg/dL].
- Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.
Who cannot join
- Known diabetes mellitus (type 1 or type 2).
- Previous history of coronary revascularization.
- Severe hepatic or renal dysfunction [alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)< 30 mL/min/1.73 m²].
- Malignant disease, autoimmune disease, or systemic inflammatory disorders.
- Current use of triglyceride-lowering medications.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Sohag University
Sohag, 82511
Remon S Adly, MD, 00201221878986, remonsaleh@yahoo.com
Alaa A Ghaleb, MD
About this study
Official title: Impact of Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).
Read the detailed description
Premature coronary artery disease (CAD), defined as CAD occurring before the age of 55 in men and 65 in women, has emerged as a growing health concern worldwide.
Insulin resistance and associated metabolic alterations are strongly implicated in premature atherosclerosis. Even in non-diabetic individuals, subclinical insulin resistance promotes endothelial dysfunction, oxidative stress, and low-grade inflammation, leading to early vascular damage.
The triglyceride-glucose (TyG) index, calculated using fasting glucose and triglyceride levels, has emerged as a cost-effective surrogate marker for insulin resistance.
- Conditions
- Triglycerides Glucose Index, Angiographic Profiling, Non-Diabetic, Premature, Coronary Artery Disease
- Being tested
- Coronary Angiographic Assessment
- Medical subject headings
- Premature Birth, Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary Angiographic AssessmentOther
Coronary angiographic assessment will be performed for all patients.
| Study group | Role | What they receive |
|---|---|---|
| Group L | Patients with a low triglyceride-glucose (TyG) index tertile. Receives: Other: Coronary Angiographic Assessment | |
| Group H | Patients with a high triglyceride-glucose (TyG) index tertile. Receives: Other: Coronary Angiographic Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of ischemia- driven revascularization
Incidence of ischemia- driven revascularization will be recorded.
Measured: 6 months post-procedure
Secondary outcomes (4)
Association between triglyceride-glucose index and single-vessel disease
The association between the triglyceride-glucose (TyG) index and single-vessel disease (SVD) will be recorded.
Measured: 6 months post-procedure
Association between triglyceride-glucose index and two-vessel disease
The association between the triglyceride-glucose index (TyG) and two-vessel disease (2VD) will be recorded.
Measured: 6 months post-procedure
Association between triglyceride-glucose index and three-vessel disease
The association between the triglyceride-glucose index (TyG) and three-vessel disease (3VD) will be recorded.
Measured: 6 months post-procedure
Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor
Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor will be recorded.
Measured: 6 months post-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2025
- Study start4 Sep 2025
- Primary completion1 Feb 2026 (estimated)
- Study completion1 Feb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Triglycerides Glucose IndexStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Remon Saleh Adly, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07154186
- Sponsor's protocol ID
- Soh-Med-25-5-5PD
- Status last verified
- Sep 2025
- First submitted
- 27 Aug 2025
- Last updated
- 5 Sep 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients
- ClinicalTrials.gov ID
- NCT07154186
- Acronym / sponsor ID
- Soh-Med-25-5-5PD
- Conditions
- Triglycerides Glucose Index, Angiographic Profiling, Non-Diabetic, Premature, Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 4 Sep 2025 (actual)
- Primary completion
- 1 Feb 2026 (estimated)
- Study completion
- 1 Feb 2026 (estimated)
- First posted
- 4 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).
Detailed description
Premature coronary artery disease (CAD), defined as CAD occurring before the age of 55 in men and 65 in women, has emerged as a growing health concern worldwide.
Insulin resistance and associated metabolic alterations are strongly implicated in premature atherosclerosis. Even in non-diabetic individuals, subclinical insulin resistance promotes endothelial dysfunction, oxidative stress, and low-grade inflammation, leading to early vascular damage.
The triglyceride-glucose (TyG) index, calculated using fasting glucose and triglyceride levels, has emerged as a cost-effective surrogate marker for insulin resistance.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group L | – | Other: Coronary Angiographic AssessmentPatients with a low triglyceride-glucose (TyG) index tertile. |
| Group H | – | Other: Coronary Angiographic AssessmentPatients with a high triglyceride-glucose (TyG) index tertile. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This cross-sectional study will be conducted at Sohag University Hospitals, following approval from the institutional ethics committee.
Key inclusion criteria (4 listed)
- Age ≥18 years old.
- Both sexes.
- Non-diabetic patients [no history of diabetes, hemoglobin A1C (HbA1C) < 6.5%, fasting glucose < 126 mg/dL].
- Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.
Key exclusion criteria (5 listed)
- Known diabetes mellitus (type 1 or type 2).
- Previous history of coronary revascularization.
- Severe hepatic or renal dysfunction [alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)< 30 mL/min/1.73 m²].
- Malignant disease, autoimmune disease, or systemic inflammatory disorders.
- Current use of triglyceride-lowering medications.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary Angiographic AssessmentCoronary angiographic assessment will be performed for all patients. | Other | Group H, Group L |
Primary outcome
Incidence of ischemia- driven revascularization
Time frame: 6 months post-procedure
Incidence of ischemia- driven revascularization will be recorded.
4 secondary outcomes
Association between triglyceride-glucose index and single-vessel disease
Time frame: 6 months post-procedure
Association between triglyceride-glucose index and two-vessel disease
Time frame: 6 months post-procedure
Association between triglyceride-glucose index and three-vessel disease
Time frame: 6 months post-procedure
Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor
Time frame: 6 months post-procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2025.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Triglycerides Glucose Index
Not yet recruitingObservational study
Metabolic and Inflammatory Indices in Lateral Epicondylitis
Lateral Epicondylitis
Not yet recruitingObservational study
Role of Triglyceride-Glucose Index and Inflammatory Biomarkers as Prognostic Tools for Progression of Diabetic Nephropathy
Diabetes Mellitus, Diabetic Nephropathy
Not yet recruitingObservational study
Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis
Rheumatoid Arthritis, Metabolic Syndrome
Not yet recruitingObservational study
Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN)
Not yet recruitingObservational study
Cf-PWV and TyG Index Study
Hypertension, Insulin Resistance Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Triglycerides Glucose Index and Angiographic Profiling, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Remon S Adly, MD (00201221878986, remonsaleh@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of ischemia- driven revascularization (time frame: 6 months post-procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.